期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 5423-5428出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S334205
关键词
castration resistant prostate cancer; androgen receptor; everolimus; next-generation sequencing
mCRPC, the advanced stage of PCa, develops resistance to ADT, associated with AR and PI3K-Akt-mTOR signaling pathway. A 64-year-old male mCRPC patient with AKT1 and AR mutations received everolimus treatment, resulting in stable disease progression with a significant drop in PSA level.
Metastatic castration resistant prostate cancer (mCRPC), the advanced stage of prostate cancer (PCa), develops resistance to first line androgen deprivation therapy (ADT). Aberrant androgen receptor (AR) and PI3K-Akt-mTOR signaling pathway are responsible for the development and progression of mCRPC. We herein describe a case of a 64-year-old male mCRPC patient with somatic AKT1 and AR mutations. The patient, who had been heavily pretreated by ADT and AR inhibitors, showed stable disease progression when he received everolimus, an mTOR inhibitor. The PSA level dropped drastically from 1493.0 ng/ mL to 237.6 ng/mL, after 3 months of treatment. The overall survival (OS) was 43 months, of which the progression-free survival (PFS) with everolimus treatment was 7 months. The administration of mTOR inhibitor, everolimus, could achieve good clinical responses along with prolonging PFS for mCRPC patients harboring AKT1 mutations. Technology in preci-sion medicine, such as targeted next-generation sequencing (NGS) of cancer-relevant genes, has promising function in personalized therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据